Vanda Pharma Secures USFDA Nod for Bysanti to Treat Schizophrenia, Acute Bipolar I
Bengaluru: The U.S. Food and Drug Administration (USFDA) has approved Vanda Pharmaceuticals' drug for the treatment of two serious mental health conditions, the company said on Friday.
The drug, branded as Bysanti, is an antipsychotic pill aimed at treating schizophrenia and acute bipolar I disorder.
The approval comes with the FDA's most serious warning of an increased risk of death in elderly patients with dementia-related psychosis.
Bysanti, chemically known as milsaperidone, belongs to a class of drugs known as atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain, which help regulate mood, stress, delusions and alertness.
Schizophrenia is a serious mental illness that can cause hallucinations and delusions, while bipolar disorder is marked by dramatic shifts in mood and energy that can disrupt sleep, judgment and daily functioning.
Vanda said it expects to launch the drug in the U.S. in the third quarter of this year.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.